Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany
Year: 2025
Type: article
Abstract: Outcomes are reported for 6 adults receiving rezafungin for chronic, hard-to-treat, invasive candidiasis (including Candida parapsilosis) during an early access program. Rezafungin was well tolerated and administered via once-weekly outpatient intravenous infusion for up to 39 weeks during the program, enabling hospital discharge and replacing daily antifungal infusions.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofaf034
Institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Guglielmo da Saliceto Hospital, Federico II University Hospital, University of Naples Federico II, Alessandro Manzoni Hospital, Aziende Socio Sanitarie Territoriali di Lecco, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Vita-Salute San Raffaele University, Provincia Autonoma di Trento, University Hospital Heidelberg, Heidelberg University, German Center for Infection Research
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,053
Funder: Mundipharma Research Limited
OpenAlex ID: W4408588284